Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $191.7 million.

  • Coherus Oncology's Cash & Current Investments rose 9619.51% to $191.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.7 million, marking a year-over-year increase of 9619.51%. This contributed to the annual value of $126.0 million for FY2024, which is 699.71% up from last year.
  • Latest data reveals that Coherus Oncology reported Cash & Current Investments of $191.7 million as of Q3 2025, which was up 9619.51% from $237.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Cash & Current Investments ranged from a high of $468.7 million in Q3 2021 and a low of $82.4 million during Q1 2025
  • In the last 5 years, Coherus Oncology's Cash & Current Investments had a median value of $191.7 million in 2022 and averaged $236.6 million.
  • In the last 5 years, Coherus Oncology's Cash & Current Investments soared by 10672.65% in 2021 and then plummeted by 6827.6% in 2025.
  • Over the past 5 years, Coherus Oncology's Cash & Current Investments (Quarter) stood at $417.2 million in 2021, then crashed by 54.05% to $191.7 million in 2022, then crashed by 38.57% to $117.7 million in 2023, then rose by 7.0% to $126.0 million in 2024, then soared by 52.13% to $191.7 million in 2025.
  • Its Cash & Current Investments stands at $191.7 million for Q3 2025, versus $237.6 million for Q2 2025 and $82.4 million for Q1 2025.